CVS Group Regulatory News (CVSG)

31 December 2025

CVS Group plc

("CVS" or the "Company")

Total Voting Rights

CVS, the UK's listed veterinary group and a leading provider of veterinary services, announces that, as of 31 December 2025, following cancellation of the Ordinary Shares purchased pursuant to the Company's share buyback programme (announced on 24 October 2025) prior to the date of this announcement, the Company's total issued share capital will consist of 70,711,273 ordinary shares of 0.2p each ("Ordinary Shares").

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts:

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

Peel Hunt LLP (Nominated Adviser & Joint Broker)   +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark 

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

Camarco (Financial PR)

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.